Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Aptol Pharma ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   33.2% 27.5% 16.8% 28.4% 20.7% 19.0% 20.6% 20.4%   Credit score (0-100)   1 2 9 1 4 7 5 5   Credit rating   C B BB B B B B B   Credit limit (kDKK)   -0.0 -0.0 0.0 -0.0 0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -102 -137 0.0 -422 414 2.4 0.0 0.0   EBITDA   -249 -441 0.0 -422 342 -128 0.0 0.0   EBIT   -249 -441 0.0 -422 342 -128 0.0 0.0   Pre-tax profit (PTP)   50.7 6.5 -0.1 -421.0 341.8 -131.3 0.0 0.0   Net earnings   -2.3 -2.5 -0.1 -334.4 308.0 -131.3 0.0 0.0   Pre-tax profit without non-rec. items   50.7 6.5 -0.1 -421 342 -131 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   50.0 50.0 17.3 -317 -9.0 -140 -190 -190   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 190 190   Balance sheet total (assets)   50.0 50.0 26.9 104 163 48.3 0.0 0.0   Net Debt   -50.0 -50.0 -0.0 -17.0 -163 -28.0 190 190     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -102 -137 0.0 -422 414 2.4 0.0 0.0   Gross profit growth   -13.8% -34.6% 0.0% 0.0% 0.0% -99.4% -100.0% 0.0%   Employees   0 0 0 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   50 50 27 104 163 48 0 0   Balance sheet change%   -33.7% 0.0% -46.1% 284.7% 57.7% -70.4% -100.0% 0.0%   Added value   -249.3 -441.1 0.0 -421.5 341.8 -128.2 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -25 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -2.0 -3.0 0.0 -1.0 1.0 -1.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   244.9% 321.9% 0.0% 100.0% 82.5% -5,248.7% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   80.8% -552.6% 0.0% -188.0% 115.3% -71.0% 0.0% 0.0%   ROI %   101.3% -552.6% 0.0% -4,853.7% 0.0% 0.0% 0.0% 0.0%   ROE %   -4.7% -4.9% -0.4% -552.8% 230.6% -124.0% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   100.0% 100.0% 64.3% -75.4% -5.2% -74.4% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   20.1% 11.3% 0.0% 4.0% -47.8% 21.9% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   0.0 0.0 2.8 0.2 0.9 0.3 0.0 0.0   Current Ratio   0.0 0.0 2.8 0.2 0.9 0.3 0.0 0.0   Cash and cash equivalent   50.0 50.0 0.0 17.0 163.4 28.0 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   50.0 50.0 17.3 -317.0 -9.0 -140.3 -95.2 -95.2   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 -422 342 -128 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 -422 342 -128 0 0   EBIT / employee   0 0 0 -422 342 -128 0 0   Net earnings / employee   0 0 0 -334 308 -131 0 0